OR502

· OncoResponse, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OR502, covering 2025-01-07 to 2025-01-07. Get the full timeline:

Most recent: Clinical Trial Update: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents [Phase 1, Phase 2]

See pricing